Neoplasia/BPH

	Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study. BJUI Compass Ng CPY, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, Shamsuddin A, Abboudi H, Agrawal S. PMID: 40678112 [PubMed]
	The impact of METTL3 on bladder cancer through m(6)A modification: a potential therapeutic target and prognostic biomarker. Front Oncol Wen D, Fu P, Shuai G, Wang Y, Yu S, Liu H, Wan W, Zou J, Zou X. PMID: 40678060 [PubMed]
	Development and validation of nomograms for predicting prognosis in patients with resectable bladder urothelial carcinoma undergoing radical cystectomy: a multicenter retrospective study. Front Oncol Ji J, Wen Z, Yao Y, Jiang L, Yang Q, Zhang G. PMID: 40678059 [PubMed]
	Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study. Front Immunol Favre-Bulle A, Stankovi, Mantaian T, Frei C, Schaefer S, Gabriel SS, Sönmez D, Aguiar-Ibáñez R. PMID: 40677709 [PubMed - indexed for MEDLINE]
	Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions. Front Immunol Wang B, Xiang Y, Liu X, Pan X, Peng L, Ma J. PMID: 40677703 [PubMed - indexed for MEDLINE]
	Moving from a registry to a learning health system: A case study of a Dutch prostate cancer registry. Learn Health Syst Belleman T, van Wijngaarden JDH, Kuppen MCP, de Groot S, van der Velden KJM, Bosch D, van Oort IM, Uyl-de Groot CA, van Deen WK. PMID: 40677594 [PubMed]
	Association of Perirectal Hydrogel Spacer Placement with Clinical Outcomes in Patients with Prostate Cancer Undergoing Radiotherapy: A Systematic Review and Meta-Analysis. World J Mens Health Kwon JK, Jeon J, Bang S, Koo KC, Cho KS, Kim DK. PMID: 40676889 [PubMed - as supplied by publisher]
	Prognostic and Predictive Value of Machine Learning-Based Biomarker and Pathomics Signatures in Patients With Prostate Cancer. Cancer Sci Zhang J, Pan J, Lin J, Cai Y, Liu Y, Lin F, Guan H, Zhou G, Wei D, Wang Z, Ma Y, Zhao Z. PMID: 40676748 [PubMed - as supplied by publisher]
	Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function. Int J Clin Oncol Nakagawa S, Ikuta K, Masuda T, Terada T. PMID: 40676437 [PubMed - as supplied by publisher]
	PSA proportion of index lesion: a novel index for predicting prostate pathology outcomes in biopsy-naÃ¯ve patients with PSAâ€‰<â€‰10Â ng/ml and PI-RADS 3 lesions. World J Urol Mo H, Hu C, Li P, Miao Z, Zhang H, Shen G, Sun J. PMID: 40676360 [PubMed - indexed for MEDLINE]
	Novel risk predictor of spontaneous rupture and hemorrhage of renal cell carcinoma based on clinical and radiographic characteristics. World J Urol Lin B, Li XD, Liu MX, Xue YT, Huang XY, Ke ZB, Chen JY, Lin F, Zheng QS, Wei Y, Xue XY, Chen SH, Xu N. PMID: 40676338 [PubMed - indexed for MEDLINE]
	PSA density correlates to pathology T stage and ISUP grade: insights from a cohort of 3568 radical prostatectomy cases. World J Urol Pattou M, Neuzillet Y, Ghoneim T, Bosset PO, Herve JM, Vanalderwerelt V, Bohin D, Lugagne PM, Soorojebally Y, Lebret T. PMID: 40676316 [PubMed - indexed for MEDLINE]
	A comparative analysis of the outcomes of RezÅ«m therapy based on prostate size: a four-year retrospective analysis. World J Urol Samir M, Mahmoud MA, Abdelmonem HA, Elrefaie M, Gad KA. PMID: 40676194 [PubMed - indexed for MEDLINE]
	Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial. Eur Urol Oncol Phillips RM, Proudfoot JA, Davicioni E, Liu Y, Spratt DE, Simko JM, Den RB, Pollack A, Rosenthal SA, Sartor AO, Sweeney CJ, Attard G, Longoria L, Patel S, Straza MW, Efstathiou JA, Shah AB, Hoffman KE, Rodgers JP, Sandler HM, Feng FY, Tran PT. PMID: 40675873 [PubMed - as supplied by publisher]
	Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer. J Nucl Med Chen Y, Zhang X, Wang X, Liu Y, Zhang J, Cui M. PMID: 40675754 [PubMed - as supplied by publisher]
	Use of hybrid quantum-classical algorithms for enhancing biomarker classification. PLoS One Astuti A, Shih PK, Lee SC, Mekala VR, Wijaya EB, Ng KL. PMID: 40674380 [PubMed - indexed for MEDLINE]
	SOX2, PIWI proteins, and MALAT1 - plasma-based emerging biomarkers for cancer detection and monitoring. PLoS One Kldiashvili E, Abiatari I, Kekelia E, Iordanishvili S, Metreveli T, Dumbadze E. PMID: 40674376 [PubMed - indexed for MEDLINE]
	FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res Maguire WF, Chi DC, Agrawal S, Joeng HK, Kim-McOlash S, Manheng W, Bulatao I, Sanchez-Solana B, Pathak A, Lee A, Han Y, Ricks TK, Hamed SS, Fiero MH, Pierce WF, Kalavar S, Ghosh S, Leighton JK, Tang S, Amiri-Kordestani L, Kluetz PG, Suzman DL. PMID: 40673886 [PubMed - as supplied by publisher]
	Identification and Validation of a Prognostic Model Based on Tumour Necrosis Factor-Related mRNAs for Kidney Renal Clear Cell Carcinoma. J Cell Mol Med Hu Z, Zhou Y, Xie L, Zhang S, Liu Y, Zhang W, Huang T. PMID: 40673609 [PubMed - indexed for MEDLINE]
	Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. Int J Cancer Okwor UE, Raitanen J, Talala K, Tammela TLJ, Taari K, Kujala P, Auvinen A. PMID: 40673336 [PubMed - as supplied by publisher]

Articles 1 - 20 / 178094

Page 1 of 8905



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy